You are here: Industry Insights > mCRC

News List

EC green light for Opdivo plus Yervoy in metastatic colorectal cancer pharmatimes
July 01, 2021
The European Commission (EC) has approved Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy immunotherapy regimen for the treatment of certain metastatic colorectal patients (mCRC), the company announced 29th.
FDA Approves New Dosing Regimen for Cetuximab americanpharmaceuticalreview
April 12, 2021
On April 6, 2021, the Food and Drug Administration approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab (Erbitux, ImClone LLC) for patients with K-Ras wild-type, EGFR-expressing colorectal ...
NICE backs Braftovi for BRAF-positive colorectal cancer pharmatimes
November 25, 2020
The National Institute for Health and Care Excellence (NICE) has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF-positive metastatic colorectal cancer.
Pierre Fabre gets EC nod for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC pharmaceutical-business-review
June 08, 2020
Pierre Fabre has secured approval from the European Commission (EC) for Braftovi (encorafenib) plus cetuximab (Erbitux) to treat adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
EU nod for new metastatic colorectal cancer combination pharmatimes
June 05, 2020
Pierre Fabre's Braftovi (encorafenib) has been approved in Europe for use alongside Erbitux (cetuximab) to treat of adults with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
Lilly’s Cyramza hits first-line NSCLC trial targets pharmatimes
March 14, 2019
Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.